Evaluation of Adjunctive Ketamine to Benzodiazepines for Management of Alcohol Withdrawal Syndrome
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Background: Adjunctive medications to manage alcohol withdrawal syndrome (AWS) in patients not adequately responding to escalating doses of benzodiazepines (BZDs) are limited. The use of the N-methyl-d-aspartate antagonist ketamine, may serve as an effective adjunct agent; however, no published data currently exist for this practice. Objective: To determine the safety and efficacy of adjunct ketamine for management of AWS. Methods: The study was a retrospective review of adult patients from April 2011 to March 2014 who were administered ketamine specifically for management of AWS. Outcomes included changes in BZD requirements and ketamine-related adverse reactions. Results: Of 235 patients screened, 23 patients met study eligibility. Ketamine was initiated primarily with toxicology consultation for significant BZD requirements or delirium tremens. The mean time to initiation of ketamine from first treatment of AWS, and total duration of therapy were 33.6 and 55.8 hours, respectively. Mean initial infusion dose and median total infusion rate during therapy were 0.21 and 0.20 mg/kg/h, respectively. There was no change in sedation or alcohol withdrawal scores in patients within 6 hours of ketamine initiation. The median change in BZD requirements at 12 and 24 hours post–ketamine initiation were −40.0 and −13.3 mg, respectively. The mean time to AWS resolution was 5.6 days. There was one documented adverse reaction of oversedation, requiring dose reduction. Conclusions: Ketamine appears to reduce BZD requirements and is well tolerated at low doses. Prospective dose range evaluations in the management of AWS would be helpful in determining its place as an adjunctive agent.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prospective evaluation of the Sedation-Agitation Scale for adult critically ill patients
Riker, R. R., Picard, J. T., & Fraser, G. L. (1999) · Critical Care Medicine · doi:10.1097/00003246-199907000-00022 · Cited by 961
Ketamine Psychedelic Therapy (KPT): A Review of the Results of Ten Years of Research
Krupitsky, E. M., & Grinenko, A. Y. (1997) · Journal of Psychoactive Drugs · doi:10.1080/02791072.1997.10400185 · Cited by 246
Rosenson, J., Clements, C., Simon, B., Vieaux, J., Graffman, S., Vahidnia, F., Cisse, B., Lam, J., & Alter, H. (2013) · The Journal of Emergency Medicine · doi:10.1016/j.jemermed.2012.07.056 · Cited by 162 · cited 1×
“The use of adjunctive agents to BZDs, such as dexmedetomidine, phenobarbital, and propofol in AWS management has been studied, with variable results.(5-17) These agents target different mechanisms, including adrenergic symptoms and alternative GABA receptors.”
BackgroundTolonen, J., Rossinen, J., Alho, H., & Harjola, V.-P. (2013) · European Journal of Emergency Medicine · doi:10.1097/mej.0b013e32835c53b3 · Cited by 45 · cited 1×
“The use of adjunctive agents to BZDs, such as dexmedetomidine, phenobarbital, and propofol in AWS management has been studied, with variable results.(5-17) These agents target different mechanisms, including adrenergic symptoms and alternative GABA receptors.”
Background
Cited by
Delirium Tremens: Assessment and Management
Grover, S., & Ghosh, A. (2018) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2018.04.012 · Cited by 416
Ketamine abuse potential and use disorder
Liu, Y., Lin, D., Wu, B., & Zhou, W. (2016) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2016.05.016 · Cited by 256
Alcohol Withdrawal Syndrome: Benzodiazepines and Beyond
Sachdeva, A. (2015) · JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH · doi:10.7860/jcdr/2015/13407.6538 · Cited by 141
Ketamine applications beyond anesthesia – A literature review
Nowacka, A., & Borczyk, M. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172547 · Cited by 129
Shah, P., McDowell, M., Ebisu, R., Hanif, T., & Toerne, T. (2018) · Journal of Medical Toxicology · doi:10.1007/s13181-018-0662-8 · Cited by 46
“Currently, only one observational study has evaluated the use ketamine in AWS [10].”
Background
Metadata
- Authors
- Wong, A., Benedict, N. J., Armahizer, M. J., & Kane-Gill, S. L.
- Venue
- Annals of Pharmacotherapy
- Publisher
- SAGE Publications
- Published
- 2014-10-16
- Volume
- 49
- Issue
- 1
- Pages
- 14-19
- ISSN
- 0012-6578 (ISSN-L)
- 1060-0280
- 1542-6270
- OpenAlex
- W2159983371
- Cited by
- 79
- References
- 4
- FWCI
- 4.27
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Evaluation of Adjunctive Ketamine to Benzodiazepines for Management of Alcohol Withdrawal Syndrome. https://app.cochat.ai/papers/10.1177/1060028014555859
- The paper
- Wong, A., Benedict, N. J., Armahizer, M. J., & Kane-Gill, S. L. (2015). Evaluation of Adjunctive Ketamine to Benzodiazepines for Management of Alcohol Withdrawal Syndrome. Annals of Pharmacotherapy. https://doi.org/10.1177/1060028014555859
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.